Last reviewed 2026-05-28 · How we verify

TDM-105795

Technoderma Medicines Inc. · Phase 1 active Small molecule ✓ Verified May 2026 Quality 10/100

TDM-105795 is a Small molecule drug developed by Technoderma Medicines Inc.. It is currently in Phase 1 development.

TDM-105795 is a small molecule being studied as a potential treatment for androgenetic alopecia. A phase 1 clinical trial (NCT04913519) is evaluating the safety of TDM-105795 in male subjects with androgenetic alopecia.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	TDM-105795
Sponsor	Technoderma Medicines Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

Abdominal pain
Application site irritation
Application site pruritus
Blood cholesterol increased
Blood creatinine increased
Back pain
Nerve compression
Alopecia areata
Hypertension
Leukopenia
Constipation
Application site erythema

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TDM-105795 CI brief — competitive landscape report
TDM-105795 updates RSS · CI watch RSS
Technoderma Medicines Inc. portfolio CI

Frequently asked questions about TDM-105795

What is TDM-105795?

TDM-105795 is a Small molecule drug developed by Technoderma Medicines Inc..

Who makes TDM-105795?

TDM-105795 is developed by Technoderma Medicines Inc. (see full Technoderma Medicines Inc. pipeline at /company/technoderma-medicines-inc).

What development phase is TDM-105795 in?

TDM-105795 is in Phase 1.

What are the side effects of TDM-105795?

Common side effects of TDM-105795 include Abdominal pain, Application site irritation, Application site pruritus, Blood cholesterol increased, Blood creatinine increased, Back pain.

Manufacturer: Technoderma Medicines Inc. — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing